(Press-News.org) Ottawa – September 16, 2014 – Physicians around the world now have guidance that can help them determine the best oral blood thinners to use for their patients suffering from blood clots in their veins, thanks to a patient of The Ottawa Hospital who asked his physician a question he couldn't answer. This new guidance is found in a study published today by JAMA, the Journal of the American Medical Association.
"Right there in the clinic, he identified an important knowledge gap for clinicians. We decided to act on it and find the answer," says hematologist Dr. Marc Carrier, who also a scientist at The Ottawa Hospital and associate professor at the University of Ottawa.
Dr. Carrier was treating Jamie Dossett-Mercer for major blood clotting in his leg veins, called deep vein thrombosis, that reached from his ankle to his groin. If one of these clots were to break off, it could travel to the lung and cause a pulmonary embolism, which is often fatal. These two common medical conditions are known together as venous thromboembolism and form the third leading cause of cardiovascular death.
In recent years, a number of new oral anticoagulants have been approved for use. Faced with eight possible therapies, Dossett-Mercer asked, "How do all these different blood thinners compare head to head?"
Dr. Carrier went looking for the answer. Although he found dozens of trials that studied the effect of different agents separately, none had analyzed all the results together.
His team reviewed 45 randomized trials (involving nearly 45,000 patients) using a process called network meta-analysis, which allows them to set a baseline treatment and compare all the other treatments to that. All the clinical trials they found compared the newer treatments to the standard of care, which is low-molecular-weight heparin (LMWH) with vitamin K antagonists.
Using the LMWH-vitamin K antagonist combination as the central node of the network, they compared safety and effectiveness with seven other anticoagulant therapies for venous thromboembolism: unfractionated heparin (UFH) with vitamin K antagonists; fondaparinux with vitamin K antagonists; LMWH with dabigatran; LMWH with edoxaban; rivaroxaban; apixaban; and LMWH alone.
While they found no major differences in effectiveness and safety, there were some notable variations.
Patients taking the UFH-vitamin K antagonist combination had a higher percentage who experienced a recurrent blood clot within three months.
Patients taking rivaroxaban and apixaban had a lower percentage who experienced a major bleeding event within three month.
"This will help physicians tailor their care according to patient characteristics," says Dr. Carrier. "For example, if I am worried about recurrent clotting, but I'm not too worried about the risk of bleeding, then I can select the drug with the best safety profile."
"I was already impressed with Dr. Carrier's exceptional care," says Dossett-Mercer. "But that he would do this research based on a patient question is just astounding."
INFORMATION:
The full article "Clinical outcomes associated with treatment of acute venous thromboembolism: A systematic review and meta-analysis" was published September 16, 2014, by JAMA. The authors received no external funding for this study.
About the Ottawa Hospital Research Institute
The Ottawa Hospital Research Institute is the research arm of The Ottawa Hospital and is an affiliated institute of the University of Ottawa, closely associated with its faculties of Medicine and Health Sciences. The Ottawa Hospital Research Institute includes more than 1,700 scientists, clinical investigators, graduate students, postdoctoral fellows and staff conducting research to improve the understanding, prevention, diagnosis and treatment of human disease. Research at Ottawa Hospital Research Institute is supported by The Ottawa Hospital Foundation.
About the University of Ottawa
The University of Ottawa is committed to research excellence and encourages an interdisciplinary approach to knowledge creation, which attracts the best academic talent from across Canada and around the world.
Contact
Paddy Moore
Communications and Public Relations
Ottawa Hospital Research Institute
padmoore@ohri.ca
(o) 613-737-8899 x73687 or (c) 613-323-5680
Kina Leclair
Media Relations Officer
University of Ottawa
kleclair@uOttawa.ca
(o) 613-562-5800 x2529 or (c) 613-762-2908
Patient's question triggers important study about blood thinners
2014-09-16
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Novel capability enables first test of real turbine engine conditions
2014-09-16
Manufactures of turbine engines for airplanes, automobiles and electric generation plants could expedite the development of more durable, energy-efficient turbine blades thanks to a partnership between the U.S. Department of Energy's Argonne National Laboratory, the German Aerospace Center and the universities of Central Florida and Cleveland State.
The ability to operate turbine blades at higher temperatures improves efficiency and reduces energy costs. For example, energy companies estimate that raising the operating temperature by 1 percent at a single electric generation ...
Boosting global corn yields depends on improving nutrient balance
2014-09-16
WEST LAFAYETTE, Ind. - Ensuring that corn absorbs the right balance of nitrogen, phosphorus and potassium is crucial to increasing global yields, a Purdue and Kansas State University study finds.
A review of data from more than 150 studies from the U.S. and other regions showed that high yields were linked to production systems in which corn plants took up key nutrients at specific ratios - nitrogen and phosphorus at a ratio of 5-to-1 and nitrogen and potassium at a ratio of 1-to-1. These nutrient uptake ratios were associated with high yields regardless of the region ...
Dry conditions and lightning strikes make for a long California fire season
2014-09-16
The fire season in California has been anything but cooperative this year. Hot conditions combined with a state-wide drought and dry lightning makes for unpleasant conditions and leads to an abundance of forest fires.
On August 12, lightning struck and started the fire that grew into the Happy Camp Complex. Currently over 113,000 acres have been affected and the fire is only 55% contained as of today. Strong winds tested fire lines yesterday (8/15), and are expected to do so again today. Despite the high winds, existing fire lines held with no spotting or expansion ...
Do wearable lifestyle activity monitors really work?
2014-09-16
Wearable electronic activity monitors hold great promise in helping people to reach their fitness and health goals. These increasingly sophisticated devices help the wearers improve their wellness by constantly monitoring their activities and bodily responses. This information is organized into companion computer programs and mobile apps.
Given the large and quickly growing market for these devices, researchers at the University of Texas Medical Branch at Galveston analyzed 13 of these activity monitors, such as those made by Fitbit, Jawbone or Nike, to compare how the ...
NASA HS3 instrument views 2 dimensions of clouds
2014-09-16
VIDEO:
Global Hawk observes the Saharan Air Layer through the Cloud Physics Lidar(CPL) during Hurricane Nadine (id 4102). More information on this topic available at:
http://www.nasa.gov/content/goddard/nasa-hs3-instrument-views-2-dimensions-of-clouds/....
Click here for more information.
NASA's Cloud Physics Lidar (CPL) instrument, flying aboard an unmanned Global Hawk aircraft in this summer's Hurricane and Severe Storm Sentinel, or HS3, mission, is studying the changing profile ...
NASA's HS3 mission covers transition of Hurricane Cristobal
2014-09-16
NASA's Global Hawk 872 aircraft flew over Hurricane Cristobal on August 28 and 29 and gathered data on the storm as it was becoming extra-tropical.
NASA's airborne Hurricane and Severe Storm Sentinel, or HS3, mission kicked off on August 26 when one of the remotely piloted Global Hawk aircraft flew a "lawnmower" or back and forth pattern over Hurricane Cristobal while gathering data using dropsondes and two other instruments. The Global Hawk dropped 81 dropsondes over Cristobal. A dropsonde is a device that measures winds, temperature, pressure and humidity as it falls ...
Results of OCT STEMI trial reported at TCT 2014
2014-09-16
WASHINGTON, DC – September 16, 2014 – The first randomized trial to examine serial optical coherence tomography (OCT) in primary percutaneous coronary intervention (PCI) was reported at the 26th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.
OCT uses light emitted from an intravascular catheter to capture high-resolution cross sectional imaging from within coronary arteries. OCT ...
Results of IVUS-CTO trial reported at TCT 2014
2014-09-16
WASHINGTON, DC – September 14, 2014 – A new study found that intravascular ultrasound (IVUS) -guided intervention in patients with chronic total occlusion (CTO) could improve outcomes compared to a conventional angiography-guided approach during percutaneous coronary intervention (PCI). The IVUS-CTO study is the first randomized trial to examine the clinical impact of IVUS guidance for CTO intervention.
Findings were reported today at the 26th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation ...
Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse?
2014-09-16
High school biology taught us that we inherit certain traits from our parents that are pre-determined. But what if you could change how these genes play out by taking certain drugs or better yet, just changing your diet? That's exactly what a team of researchers at the Boston University School of Medicine (BUSM) have proposed through their research of epigenetics research.
Epigenetics regulates gene expression in a reversible manner by chemically modifying DNA and histone proteins, which prevent permanent mutations or alterations within the gene themselves. Throughout ...
Results of DKCRUSH-VI trial reported at TCT 2014
2014-09-16
WASHINGTON, DC – September 14, 2014 – A new study found that fractional flow reserve (FFR)-guided provisional side branch (SB) stenting of true coronary bifurcation lesions yields similar outcomes to the current standard of care. The DKCRUSH-VI clinical trial is the first study to compare FFR-guided and angiography-guided stenting.
Findings were reported today at the 26th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in ...